Company
Grifols, SA
Headquarters: Barcelona, Spain
Founded: 1940
Employees: 23,245
CEO: Mr. Raimon Grifols Roura
Market Cap
€5.55 Billion
EUR as of Jan. 1, 2025
US$5.77 Billion
Grifols, SA Categories
Spain Healthcare Drug Manufacturers—GeneralSpain Healthcare Spain Drug Manufacturers—General
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—General
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
| Merck | $244.44 B |
| Roche | $219.35 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumÂfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringÂto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | €7.01 B |
| EBITDA | €1.28 B |
| Gross Profit TTM | €2.75 B |
| Profit Margin | 2.31% |
| Operating Margin | 20.06% |
| Quarterly Revenue Growth | 12.20% |
Stocks & Indices
Grifols, SA has the following listings and related stock indices.
Stock: BME: GRF wb_incandescent
Stock: BMV: GRFPN wb_incandescent
Stock: FSX: G0FB wb_incandescent
Stock: FSX: OZTA wb_incandescent
Stock: NASDAQ: GRFS wb_incandescent
Stock: OTC: GIFLF wb_incandescent
Stock: OTC: GIFOF wb_incandescent
Stock: OTC: GIKLY wb_incandescent
Product & Services
Plasma derivatives, in vitro diagnostic products, non-biological products for laboratories and hospitals
Key People
Víctor Grífols Deu and Raimon Grifols Roura (Chairmen and CEOs)